Results From the First-in-Human Study With Ozanimod, a Novel, Selective Sphingosine-1-Phosphate Receptor Modulator.

about

Cardiac Safety of Ozanimod, a Novel Sphingosine-1-Phosphate Receptor Modulator: Results of a Thorough QT/QTc Study.Effects of High- and Low-Fat Meals on the Pharmacokinetics of Ozanimod, a Novel Sphingosine-1-Phosphate Receptor Modulator.

P2860

Q46025818-4465D02D-DD24-4D68-99AA-72E18E69A7EC Q50070747-EE3426B1-217E-4F93-A1F0-54AC14870A3E

P2860

Results From the First-in-Human Study With Ozanimod, a Novel, Selective Sphingosine-1-Phosphate Receptor Modulator.

Item

http://www.wikidata.org/entity/Q41052913

description

2017 nî lūn-bûn

@nan

2017年の論文

@ja

2017年学术文章

@wuu

2017年学术文章

@zh-cn

2017年学术文章

@zh-hans

2017年学术文章

@zh-my

2017年学术文章

@zh-sg

2017年學術文章

@yue

2017年學術文章

@zh

2017年學術文章

@zh-hant

name

Results From the First-in-Huma ...... -Phosphate Receptor Modulator.

@en

type

Item

label

Results From the First-in-Huma ...... -Phosphate Receptor Modulator.

@en

prefLabel

Results From the First-in-Huma ...... -Phosphate Receptor Modulator.

@en

P1476

Results From the First-in-Huma ...... -Phosphate Receptor Modulator.

@en

P2093

Allan D Olson

http://www.w3.org/2001/XMLSchema#string

Gregg A Timony

http://www.w3.org/2001/XMLSchema#string

Heather Smith

http://www.w3.org/2001/XMLSchema#string

Hugh Rosen

http://www.w3.org/2001/XMLSchema#string

Jeffrey P Hartung

http://www.w3.org/2001/XMLSchema#string

Jennifer L Brooks

http://www.w3.org/2001/XMLSchema#string

Jonathan Q Tran

http://www.w3.org/2001/XMLSchema#string

Marcus F Boehm

http://www.w3.org/2001/XMLSchema#string

Paul A Frohna

http://www.w3.org/2001/XMLSchema#string

Robert J Peach

http://www.w3.org/2001/XMLSchema#string

P2860

Sphingosine 1-phosphate receptor modulators in multiple sclerosis

Oral fingolimod or intramuscular interferon for relapsing multiple sclerosis

Multiple sclerosis

Multiple-dose tolerability, pharmacokinetics, and pharmacodynamics of ponesimod, an S1P1 receptor modulator: favorable impact of dose up-titration.

Effect of ponesimod, a selective S1P1 receptor modulator, on the QT interval in healthy individuals.

Ozanimod (RPC1063) is a potent sphingosine-1-phosphate receptor-1 (S1P1 ) and receptor-5 (S1P5 ) agonist with autoimmune disease-modifying activity.

Ozanimod Induction and Maintenance Treatment for Ulcerative Colitis.

Enhancement of capillary leakage and restoration of lymphocyte egress by a chiral S1P1 antagonist in vivo.

Oral fingolimod (FTY720) for relapsing multiple sclerosis.

Sphingosine-1-phosphate receptor-1 (S1P1) is expressed by lymphocytes, dendritic cells, and endothelium and modulated during inflammatory bowel disease

P304

988-996

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1002/JCPH.887

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P577

2017-04-11T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

28398597

http://www.w3.org/2001/XMLSchema#string

P932

5516232

http://www.w3.org/2001/XMLSchema#string

Results From the First-in-Human Study With Ozanimod, a Novel, Selective Sphingosine-1-Phosphate Receptor Modulator.

about

P2860

P2860

Results From the First-in-Human Study With Ozanimod, a Novel, Selective Sphingosine-1-Phosphate Receptor Modulator.

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P304

P31

P356

P433

P478

P577

P698

P932

P356

P1433

P1476

P2093

P2860

P304

P31

P356

P433

P478

P577

P698

P932